OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado. Show more

6707 Winchester Circle, Boulder, CO, 80301, United States

Biotechnology
Healthcare
Start AI Chat

Market Cap

33.19M

52 Wk Range

$1.70 - $5.60

Previous Close

$2.45

Open

$2.45

Volume

103,109

Day Range

$2.45 - $2.60

Enterprise Value

-44.67M

Cash

70.33M

Avg Qtr Burn

-13.04M

Insider Ownership

1.79%

Institutional Own.

88.91%

Qtr Updated

09/30/25